488 related articles for article (PubMed ID: 28972876)
1. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
[TBL] [Abstract][Full Text] [Related]
2. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
Manavalan TT; Teng Y; Litchfield LM; Muluhngwi P; Al-Rayyan N; Klinge CM
PLoS One; 2013; 8(4):e62334. PubMed ID: 23626803
[TBL] [Abstract][Full Text] [Related]
3. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
Tsou SH; Chen TM; Hsiao HT; Chen YH
PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
[TBL] [Abstract][Full Text] [Related]
4. 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.
Kong X; Ding X; Li X; Gao S; Yang Q
Cancer Sci; 2015 Aug; 106(8):982-9. PubMed ID: 26011542
[TBL] [Abstract][Full Text] [Related]
5. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
6. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.
Sun L; Yao Y; Liu B; Lin Z; Lin L; Yang M; Zhang W; Chen W; Pan C; Liu Q; Song E; Li J
Oncogene; 2012 Jan; 31(4):432-45. PubMed ID: 21725369
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
Sun FD; Wang PC; Luan RL; Zou SH; Du X
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
[TBL] [Abstract][Full Text] [Related]
8. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
9. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
10. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
11. Role of p38γ MAPK in regulation of EMT and cancer stem cells.
Xu M; Wang S; Wang Y; Wu H; Frank JA; Zhang Z; Luo J
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3605-3617. PubMed ID: 30251680
[TBL] [Abstract][Full Text] [Related]
12. The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin.
Han B; Huang J; Han Y; Hao J; Wu X; Song H; Chen X; Shen Q; Dong X; Pang H; Cai L
Int J Biol Macromol; 2019 Mar; 125():544-556. PubMed ID: 30537505
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
[TBL] [Abstract][Full Text] [Related]
14. miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer.
Chu S; Liu G; Xia P; Chen G; Shi F; Yi T; Zhou H
Oncol Rep; 2017 Oct; 38(4):2401-2407. PubMed ID: 28765915
[TBL] [Abstract][Full Text] [Related]
15. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.
Yang Q; Wang Y; Lu X; Zhao Z; Zhu L; Chen S; Wu Q; Chen C; Wang Z
Oncotarget; 2015 Feb; 6(5):3268-79. PubMed ID: 25605244
[TBL] [Abstract][Full Text] [Related]
16. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
17. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.
Chen Y; Sun Y; Chen L; Xu X; Zhang X; Wang B; Min L; Liu W
Mol Med Rep; 2013 May; 7(5):1579-84. PubMed ID: 23546450
[TBL] [Abstract][Full Text] [Related]
18. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics.
Chekhun VF; Borikun TV; Lukianova NY
Exp Oncol; 2016 Mar; 38(1):26-30. PubMed ID: 27031715
[TBL] [Abstract][Full Text] [Related]
19. miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells.
Hu SH; Wang CH; Huang ZJ; Liu F; Xu CW; Li XL; Chen GQ
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(23):5002-5008. PubMed ID: 27981531
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-520c-3p negatively regulates EMT by targeting IL-8 to suppress the invasion and migration of breast cancer.
Tang CP; Zhou HJ; Qin J; Luo Y; Zhang T
Oncol Rep; 2017 Nov; 38(5):3144-3152. PubMed ID: 29048659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
